NCT07496229 2026-04-17Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)Dizal PharmaceuticalsPhase 1/2 Recruiting165 enrolled
NCT06561048 2026-04-08Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.Phase 3 Recruiting150 enrolled
NCT06035497 2026-04-06A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Bristol-Myers SquibbPhase 1/2 Active not recruiting85 enrolled
NCT06492304 2026-04-03A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesCRISPR TherapeuticsPhase 1/2 Completed12 enrolled
NCT06854653 2026-03-31A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLPrescient Therapeutics, Ltd.Phase 2 Recruiting115 enrolled